Published in N Engl J Med on March 29, 2009
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events | NCT00239681
Role of Immune Responses After Acute Myocardial Infarction (BATTLE-AMI) | NCT02428374
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study. BMJ (2014) 3.34
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med (2010) 2.94
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2009) 2.55
Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med (2011) 2.40
Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol (2011) 2.18
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13
Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost (2013) 2.13
Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg (2013) 2.05
Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88
Risk factors for venous and arterial thrombosis. Blood Transfus (2010) 1.58
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest (2012) 1.51
Beneficial effects of perioperative statins for major pulmonary resection. J Thorac Cardiovasc Surg (2014) 1.38
The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ (2012) 1.36
New insights into the mechanisms of venous thrombosis. J Clin Invest (2012) 1.32
New players in haemostasis and thrombosis. Thromb Haemost (2014) 1.29
Anti-inflammatory therapies for cardiovascular disease. Eur Heart J (2014) 1.28
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
Non-cardiovascular effects associated with statins. BMJ (2014) 1.24
Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica (2009) 1.15
Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost (2012) 1.13
Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis (2012) 1.13
C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost (2009) 1.11
Epidemiology of venous thromboembolism. Nat Rev Cardiol (2015) 1.07
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
Management of submassive pulmonary embolism. Circulation (2010) 1.03
The epidemiology of venous thromboembolism. J Thromb Thrombolysis (2016) 1.00
CRP in cardiovascular disease. Herz (2009) 1.00
Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med (2012) 0.99
Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res (2013) 0.98
Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg (2011) 0.97
Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep (2013) 0.95
Current treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol (2010) 0.93
Low fingertip temperature rebound measured by digital thermal monitoring strongly correlates with the presence and extent of coronary artery disease diagnosed by 64-slice multi-detector computed tomography. Int J Cardiovasc Imaging (2009) 0.93
Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends Cardiovasc Med (2013) 0.91
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res (2012) 0.89
Hyperlipidemia as an instigator of inflammation: inaugurating new approaches to vascular prevention. J Am Heart Assoc (2012) 0.89
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences. Vasc Health Risk Manag (2009) 0.89
Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study. BMJ Open (2013) 0.88
Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost (2014) 0.86
Acute pulmonary embolism. Part 1: epidemiology and diagnosis. Nat Rev Cardiol (2010) 0.85
Systemic inflammation impairs tissue reperfusion through endothelin-dependent mechanisms in cerebral ischemia. Stroke (2014) 0.85
Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women's Health Study. J Thromb Haemost (2012) 0.85
Lipophilic Statins and Aldosterone Secretion: A Bridge Too Far? Circulation (2015) 0.85
Pleiotropic effects of statins. Indian J Endocrinol Metab (2015) 0.84
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging (2010) 0.84
ROCKs as immunomodulators of stroke. Expert Opin Ther Targets (2012) 0.84
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J (2010) 0.83
Role of statins in the development and progression of age-related macular degeneration. Retina (2013) 0.82
Rosuvastatin reduces neointima formation in a rat model of balloon injury. Eur J Med Res (2010) 0.82
Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Thromb J (2014) 0.81
High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study. Haematologica (2011) 0.81
Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring. PLoS One (2015) 0.81
Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. Clinicoecon Outcomes Res (2012) 0.81
Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Vasc Med (2014) 0.79
Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy. Oncologist (2012) 0.79
Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic disease. PLoS One (2014) 0.79
Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol (2013) 0.79
Statins and venous thrombosis: a story too good to be true? PLoS Med (2012) 0.79
Fatal pulmonary embolism in hospitalized patients: a large autopsy-based matched case-control study. Clinics (Sao Paulo) (2013) 0.78
Current Perspectives on rosuvastatin. Integr Blood Press Control (2013) 0.78
Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatr (2011) 0.78
The association of statin therapy with the risk of recurrent venous thrombosis. J Thromb Haemost (2016) 0.78
Effects of statin on circulating microRNAome and predicted function regulatory network in patients with unstable angina. BMC Med Genomics (2015) 0.78
Environmental and Genetic Risk Factors Associated with Venous Thromboembolism. Semin Thromb Hemost (2016) 0.78
The periprostatic venous plexus: an unusual source of fatal pulmonary embolism during corporoplasty. Int J Legal Med (2016) 0.77
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
Clustering patterns of comorbidities associated with in-hospital death in hospitalizations of US adults with venous thromboembolism. Int J Med Sci (2013) 0.77
Role of statins in coronary artery disease. Chonnam Med J (2013) 0.77
Novel mediators and biomarkers of thrombosis. J Thromb Thrombolysis (2014) 0.77
Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study. Drug Saf (2017) 0.76
Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study. Thromb Res (2015) 0.76
Association of Traditional Cardiovascular Risk Factors with Venous Thromboembolism: An Individual Participant Data Meta-analysis of Prospective Studies. Circulation (2016) 0.76
JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. World J Cardiol (2011) 0.75
Statin use decreases coagulation in users of vitamin K antagonists. Eur J Clin Pharmacol (2016) 0.75
Atorvastatin-related thrombocytopenic purpura. BMJ Case Rep (2010) 0.75
Current statins show calcium channel blocking activity through voltage gated channels. BMC Pharmacol Toxicol (2016) 0.75
The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study. BMJ Open (2014) 0.75
Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thromb Res (2015) 0.75
ACP Journal Club. Rosuvastatin reduced venous thromboembolism in healthy older adults with elevated C-reactive protein levels. Ann Intern Med (2009) 0.75
Duration of anticoagulation for venous thromboembolic events. Circulation (2014) 0.75
The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research. Rambam Maimonides Med J (2015) 0.75
Perioperative protective effects of statins. F1000 Med Rep (2010) 0.75
Association between previous history of gout attack and risk of deep vein thrombosis - a nationwide population-based cohort study. Sci Rep (2016) 0.75
Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative. BMJ Open (2015) 0.75
The association of F11 genetic variants with the risk of incident venous thrombosis among women, by statin use. Thromb Haemost (2015) 0.75
Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study. Clin Sci (Lond) (2014) 0.75
Identification of Genetic Variants Linking Protein C and Lipoprotein Metabolism: The ARIC Study (Atherosclerosis Risk in Communities). Arterioscler Thromb Vasc Biol (2017) 0.75
Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions. Curr Cardiol Rev (2016) 0.75
The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis. BMC Pharmacol Toxicol (2013) 0.75
Expanding the clinical spectrum of OSA--an association with pulmonary embolism? Sleep (2010) 0.75
Acute right ventricular failure caused by concomitant coronary and pulmonary embolism: successful treatment with endovascular coronary and pulmonary thrombectomy. Eur Heart J Acute Cardiovasc Care (2013) 0.75
Coronary atherosclerosis burden is not advanced in patients with β-thalassemia despite premature extracardiac atherosclerosis: a coronary artery calcium score and carotid intima-media thickness study. J Geriatr Cardiol (2016) 0.75
Serum uric acid is associated with increased risk of idiopathic venous thromboembolism in high HDL-C population: A case-control study. Exp Ther Med (2016) 0.75
Statins and acute lung injury: Holy Grail or the next to fail? Crit Care Med (2012) 0.75
Statins: the good, the bad and the ugly. CMAJ (2012) 0.75
Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. Int J Cardiol (2016) 0.75
Lipid levels and risk of venous thrombosis: results from the MEGA-study. Eur J Epidemiol (2017) 0.75
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Calculating the number needed to treat for trials where the outcome is time to an event. BMJ (1999) 5.06
Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2000) 4.29
Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet (2007) 3.66
An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost (2000) 3.21
Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation (2007) 3.20
Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med (2002) 3.15
A prospective study of risk factors for pulmonary embolism in women. JAMA (1997) 3.12
Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med (2002) 3.04
Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol (2005) 3.02
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation (2005) 2.26
Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol (2008) 2.03
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost (2009) 1.95
Statins and blood coagulation. Arterioscler Thromb Vasc Biol (2004) 1.89
HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost (2004) 1.85
Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med (2001) 1.82
Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913". Arch Intern Med (1999) 1.76
Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol (2002) 1.65
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost (2005) 1.19
High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation (2007) 1.16
HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost (2008) 1.15
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med (2007) 1.14
High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood (2008) 1.07
Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. J Thromb Haemost (2009) 1.05
Arterial disease and venous thrombosis: are they related, and if so, what should we do about it? J Thromb Haemost (2006) 1.04
Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost (2006) 1.02
Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol (2004) 0.95
Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost (2004) 0.92
Do we care if statins prevent venous thromboembolism? J Thromb Haemost (2004) 0.85
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Inflammation and atherosclerosis. Circulation (2002) 20.77
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 11.51
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Progress and challenges in translating the biology of atherosclerosis. Nature (2011) 9.41
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Statin use and reduced cancer-related mortality. N Engl J Med (2012) 8.51
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med (2007) 7.96
Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med (2008) 7.95
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med (2009) 7.62
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One (2008) 7.16
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med (2012) 5.98
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med (2007) 5.95
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 5.59
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation (2003) 5.34
Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol (2012) 5.12
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63